172@29@17@243!~!172@29@0@53!~!|news|business|markets|big-bull-jhunjhunwala-cash-out-in-5-stocks-in-sep-quarter-7-stocks-which-rose-100-300-2418187.html!~!news|moneycontrol|com!~!|controller|infinite_scroll_article.php!~!is_mobile=false
Moneycontrol
Subscribe to Moneycontrol Pro and get 365 bonus InterMiles! Use Code: INTERMILES
Last Updated : Oct 24, 2017 09:31 AM IST | Source: Moneycontrol.com

Top 7 stocks from Rakesh Jhunjhunwala’s portfolio which rose 100-300% in 2017

Jhunjhunwala is optimistic on the story of financial savings and feels a large part of savings being invested into equity has just started.

The big bull, Rakesh Jhunjhunwala partner RARE Enterprises decided to pare his stake in 5 companies in which his holding fell below the 1 percent for the quarter ended September; however, he added one stock in his portfolio in the same period.

We have compiled a list of stocks from the shareholding pattern declared by companies for the quarter ended September 2017 in which Rakesh Jhunjhunwala holds more than 1 percent.

He usually makes a purchase under following names -- Rakesh Jhunjhunwala, Jhunjhunwala Rakesh Radheshyam, Rekha Jhunjhunwala, and Jhunjhunwala Rekha Rakesh.

Close

Rakesh Jhunjhunwala has 27 stocks in his portfolio with a public shareholding of over 1 percent, according to data compiled from Capitaline. He raised stake in 5 companies while decreased in 7. Jhunjhunwala maintained his stake in comparison to June quarter in as many as 15 companies.

Out of 27 stocks in his portfolio for the quarter ended September 2017, seven stocks have already more than doubled investors’ wealth so far in the year 2017.

Stocks which rose 100-300 percent include companies like Geojit Financial Services which rose 292 percent, followed by Prakash Industries gained 216 percent, Edelweiss Finance surged 195 percent in the same period.

Image224102017

However, he reduced stake below 1 percent in the September quarter in as many as five stocks which include names like Viceroy Hotels, Aurobindo Pharma, Bilcare, JPAssociates, and TV18 Broadcast.

Jhunjhunwala bought a stake in Fortis Healthcare, the only stock he added in his portfolio with a public shareholding of up to 1.54 percent. Fortis Healthcare Limited is a leading integrated healthcare delivery service provider in India. The stock has plunged nearly 20 percent in so far in the year 2017.

He raised stake in five stocks from June quarter which includes names like Prakash Industries, NCC, Lupin, Fortis Healthcare (new entrant) and Crisil.

Jhunjhunwala reduced stake slightly in 7 companies which include names like Titan Company, Karur Vysya Bank, Crisil, Federal Bank, Geojit Financial Services, Firstsource Solutions, and Edelweiss Financials.

He maintained the stake in 15 companies which include companies like Escorts, ION Exchange, VIP Industries, Agro Tech Foods, Dewan Housing, MCX, Orient Cement, Delta Corp, and Autoline Industries etc. among others.

Image124102017

Positive on Samvat 2074; pharma top bet

The eternal bull of D-Street is positive on Samvat 2074 and investors has nothing to worry about as Indian market is in a very long bull market which is backed by strong fundamentals and a gush of domestic savings in the Indian equity markets.

Rakesh Jhunjhunwala of Rare enterprises in an interview with CNBC-TV18 last week said that investors are staring at a ‘very very long bull market’. The reasons for this bullish sentiment are alive and fundamentals will only improve with every passing day.

Jhunjhunwala is optimistic on the story of financial savings and feels a large part of savings being invested into equity has just started.

The Assets under Management (AUM) of the Indian mutual fund industry hit another record high as AUM came in at Rs. 20.40 lakh crore in September 2017 as against Rs. 20.59 lakh crore in August 2017.

The big bull is betting big on the pharmaceutical space. For the sector, he said, everything that could go wrong has already gone wrong and the worst is behind.

He expects pharmaceutical sector in India to grow at 15 percent every year and believes large pharma businesses in India will do well regardless of what happens in the US.

Disclaimer: The stocks listed above are not recommendations. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
First Published on Oct 24, 2017 08:34 am
Sections